| Title |
Budesonide for maintenance of remission in Crohn's disease
|
|---|---|
| Published in |
Cochrane database of systematic reviews, August 2014
|
| DOI | 10.1002/14651858.cd002913.pub3 |
| Pubmed ID | |
| Authors |
M Ellen Kuenzig, Ali Rezaie, Cynthia H Seow, Anthony R Otley, A. Hillary Steinhart, Anne Marie Griffiths, Gilaad G Kaplan, Eric I Benchimol |
| Abstract |
Corticosteroids are effective for induction, but not maintenance of remission in Crohn's disease. Significant concerns exist regarding the risk for adverse events, particularly when corticosteroids are used for long treatment courses. Budesonide is a glucocorticoid with limited systemic bioavailability due to extensive first-pass hepatic metabolism and is effective for induction of remission in Crohn's disease. |
Twitter Demographics
The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 29% |
| Turkey | 1 | 14% |
| France | 1 | 14% |
| Unknown | 3 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Practitioners (doctors, other healthcare professionals) | 1 | 14% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 253 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | <1% |
| Chile | 1 | <1% |
| Italy | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 248 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 32 | 13% |
| Student > Master | 31 | 12% |
| Student > Bachelor | 30 | 12% |
| Researcher | 23 | 9% |
| Other | 18 | 7% |
| Other | 54 | 21% |
| Unknown | 65 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 97 | 38% |
| Nursing and Health Professions | 26 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 6% |
| Psychology | 8 | 3% |
| Agricultural and Biological Sciences | 5 | 2% |
| Other | 29 | 11% |
| Unknown | 74 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2021.
All research outputs
#4,560,666
of 23,339,727 outputs
Outputs from Cochrane database of systematic reviews
#7,008
of 12,628 outputs
Outputs of similar age
#45,538
of 237,223 outputs
Outputs of similar age from Cochrane database of systematic reviews
#134
of 225 outputs
Altmetric has tracked 23,339,727 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,628 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 32.9. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,223 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 225 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.